

# Chapter \_\_. Chronic Lower Respiratory Tract Diseases

Peter Burney, Rogelio Perez-Padilla, Guy Marks, Gary Wong, Eric Bateman, and Deborah Jarvis

Boxes: 2

Figures: 2 [4 panels]

Maps: 0

Tables:

Word count: 15, 887 - 415; including 5,200 in references

Graphics requiring permission: 2

[Box 1 = 415 words (online only); Box 2 = 536 words]

- I. Introduction
- II. Distribution of Disease, Disease Burden, Risk Factors, and Primary Prevention
  - A. Asthma
  - B. Chronic Airway Obstruction and Chronic Obstructive Pulmonary Disease
  - C. Idiopathic Low FVC
  - D. Restrictive Lung Disease and Fibrosis
  - E. Chronic Bronchitis and Bronchiectasis
- III. Primary Prevention of Chronic Lung Diseases
- IV. Principles of Care
- V. Management
  - A. Asthma
    1. Diagnosis
    2. Assessment
    3. Pharmacological Management
    4. Barriers to Care
  - B. Chronic Airway Obstruction
    1. Diagnosis
    2. Clinical Course and Management
    3. Pharmacological Management
    4. Management of Exacerbations
  - C. Idiopathic Low FVC
  - D. Restrictive and Fibrosing Lung Diseases
    1. Diagnosis
    2. Treatment
  - E. Bronchiectasis
- VI. Systems and Organization of Care
- VII. Conclusions

Corresponding author: PGJ Burney, National Heart and Lung Institute, Imperial College, London.  
[P.burney@imperial.ac.uk](mailto:P.burney@imperial.ac.uk)

## Introduction

Chronic respiratory diseases (CRDs) are common and increasing in relative terms as causes of disability and death. CRD refers to non-infectious conditions of the lung and respiratory tract, excluding cancers and trauma. The focus of this chapter is on the more common of these conditions, but we have been influenced by the availability of data. Not addressed are two common conditions of the upper respiratory tract, allergic and chronic rhino-sinusitis, that cause considerable disability but are not associated with substantial mortality. Smoking cessation and reduction or elimination of other harmful exposures is an important component of the management of any chronic respiratory disease. Tobacco cessation is addressed in chapter 4 in this volume and also in the volume on cancer.

The two main conditions contributing to death and disability are asthma and chronic obstructive pulmonary disease (COPD). Both are clinical diagnoses and are associated with narrowed airways and difficulty exhaling. Asthma has become more common in many countries in parallel with an increasing prevalence of allergic sensitization. COPD, in particular, is an increasing burden as the world's population ages and tobacco smoking increases in many low- and middle-income countries (LMICs), especially among women. The effects of both diseases and mortality from all causes tend to be greater in those with smaller lungs, and smaller lung volumes are more common in LMICs.

Although these diseases are rarely curable, effective treatments to reduce both disability and death are available and affordable.

## Distribution of Disease, Disease Burden, Risk Factors and Primary Prevention

### Asthma

Asthma is a common cause of morbidity in children and adults; it is generally amenable to treatment with effective low-cost medications that have minimal long-term adverse side effects. An estimated 300 million people worldwide suffer from asthma; more than 250,000 asthma-related deaths occur annually. Asthma ranks 42nd in the list of diseases and conditions that cause death globally (Lozano and others 2013) but 14th in the list of causes of years lived with disability (YLDs) (Salomon and others 2012; Vos and others 2012). The disease generally has an early onset and tends to persist throughout life; deaths among young people with asthma are rare.

The prevalence of asthma has been increasing, although this increase may be slowing or even reversed in some countries. In LMICs, a very low prevalence has been recorded in rural compared with urban environments (Calvert and Burney 2005; Keeley and Gallivan 1991; Perzanowski and others 2002), but the prevalence in LMICs is likely to rise as they become more urbanized. The increased prevalence in urban populations is associated with an increase in positive skin tests to allergens which is partly explained by increases in body mass index (Calvert J, Burney P. Effect of body mass on exercise induced bronchoconstriction and atopy in African children. *J Allergy Clin Immunol* 2005; 116 (4): 773-9) and in part by the quality of the urban diet (Hooper R, Calvert J, Thompson RL, Deetlefs ME, Burney, P. Urban/rural differences in diet and atopy in South Africa. *Allergy* 2008; 63: 425–431) Within urban communities, socioeconomic deprivation is associated with more frequent symptoms and exacerbations of asthma, use of emergency services, hospitalizations

and mortality, likely due to less access to effective therapy and health services (Poyser MA, Nelson H, Ehrlich RI, Bateman ED, Parnell S, et al 2002).

Consistent with these findings prevalence rates vary widely for children and adults. The first phase of the ISAAC study provided findings for 463,801 children ages 13 to 14 years (155 centers in 56 countries) and 257,800 children ages six to seven years (91 centers in 38 countries) (Asher and others 1998). The prevalence of asthma symptoms was based on a positive response to the question, "Have you had wheezing or whistling in the chest in the last 12 months?" For the younger and older children, there was an approximate twentyfold range of prevalence, with the highest rates generally in countries with a high gross national income as defined by the World Bank, but severe asthma was proportionally more common in low-income areas of Africa and South and South East Asia (Lai and others 2009).

The World Health Survey interviewed adults over age 18 years on six continents using questions derived from the European Community Respiratory Health Survey (ECRHS) on wheezing and on diagnosed asthma (Sembajwe and others 2010). The prevalence of diagnosed asthma ranged from 2 percent in Vietnam to 33 percent in Australia. The lowest mean prevalence was found in the middle-income countries; however, the percentage of sites with a prevalence above 10 percent rose from 19 percent (4/21) in the countries with the lowest income (less than US\$3,000), to 59 percent (10/17) in countries with intermediate incomes (£3,000, US\$7,999), and to 73 percent (22/30) in countries with per capita incomes above \$US8,000 per year.

Asthma runs in families, but the basis for inheritance is complex; the observation that up to 30 percent of childhood asthma is related to genetics needs further study (Moffatt and others 2010). and is less strong for adults. Asthma is associated with allergy, and both allergy and allergic asthma are less common in poorer countries (Weinmayr and others 2010); non-allergic wheeze is fairly evenly distributed by levels of poverty. Many risk factors have been associated with the onset of disease and with disease exacerbations. Potentially remediable risk factors for disease onset that are potentially remediable include parental (and even grandparental) smoking, obesity, poor diet, and workplace exposure to allergens. Evidence for dietary factors preventing asthma is inconclusive; studies with improved design are needed. (Nurmatov, Devereux, and Sheikh 2011). Adult-onset asthma caused by occupational exposures are preventable by appropriate measures to limit exposures in the workplace and by screening of exposed workers to detect early signs of disease. Exacerbations are associated with viral upper respiratory tract infections, especially in children, and with exposure to airborne allergens in the outdoor environment; these factors are more difficult to avoid.

Most people with asthma develop symptoms in childhood. During adolescence, symptoms of the disease remit in up to 40 percent of cases; however, in approximately 50 percent of these cases, for unknown reasons, symptoms return during adult life. Asthma that begins in adult life tends to be more severe, is more common in women, and exposure to cigarette smoke and an inadequate intake of antioxidants may play a role (Larkin and others 2015).

Death rates from asthma are relatively low, but are higher in older adults than in children or young adults (Lozano and others 2013). In countries with efficient programs for diagnosing and treating asthma, death rates of less than one per million population are being achieved. Accordingly, from a public health perspective, asthma deaths need to be viewed as preventable. Poorly controlled

asthma is also a risk factor for the development of fixed airway obstruction in later life (Obaseki and others 2014).

## Chronic Airway Obstruction and Chronic Obstructive Pulmonary Disease (COPD)

Chronic airway obstruction is defined in terms of the ratio of the one-second Forced Expiratory Volume ( $FEV_1$ ) to the Vital Capacity (VC). The  $FEV_1$  is the volume of air that can be blown out with maximum force from a full inspiration in one second. Vital capacity is the maximum volume of air that can expired from a full inspiration in one breath and is generally measured as the forced vital capacity (FVC) in the same manoeuvre as the  $FEV_1$ . The VC and FVC are measures of lung size, and the  $FEV_1$  is a measure of flow over the first second of expiration; the  $FEV_1/FVC$  ratio is a measure of flow adjusted for lung size.

This section focuses on irreversible obstruction, the presence of a low  $FEV_1/FVC$  ratio following administration of a bronchodilator. There has been debate about the best index for measuring this. The Global Initiative for Obstructive Lung Disease (GOLD) (Global Initiative 2014) has recommended a single index for all ages—the fixed ratio of  $FEV_1:FVC$  of 0.7. However, as this ratio declines universally with age, an alternative approach is to define a low ratio as being a value below the lower limit of normal (Miller and others 2005; Swanney and others 2008). The lower limit of normal is the level of the  $FEV_1:FVC$  exceeded in 95 percent of the normal population, generally defined as never smokers with no respiratory diagnosis and (sometimes) no respiratory symptoms. This measure takes account of the age of the person. The ratio is affected by age and disease, but does not seem to be affected by other factors, such as height and gender and ethnicity (Hankinson, Odenrantz, and Fedan 1999).

Chronic Obstructive Pulmonary Disease (COPD) is the most common cause of chronic airflow limitation. In COPD obstruction arises either because the small airways are narrowed or obstructed by inflammation (Small Airway Disease) or, because, as in emphysema, lung tissue is destroyed and loses elasticity, which is required for keeping airways open during exhalation. In chronic asthma, bronchoconstriction, thickening of airway walls due to predominantly allergic inflammation, oedema, an increase in smooth muscle, and some subtle scar tissue narrow airways. These conditions are discussed below.

Lung function may be tested before or after inhalation of a bronchodilator to increase the caliber of the airway. Pre-bronchodilator obstruction that reverses after a bronchodilator is administered is described as reversible obstruction, and demonstrating this at some stage, is considered necessary for the diagnosis of asthma. Up to two-thirds of patients with COPD show evidence of reversible obstruction, but it is generally of a lesser magnitude. Increases of more than 400 ml suggest a diagnosis of asthma. Ninety-five percent of the normal population has an increase of  $FEV_1$  following 200 mg inhaled salbutamol of less than 12 percent (Tan and others 2012).

Although family studies suggest that approximately 50 percent of the variation in lung function is due to genetic factors, only a very small part of this variation has been attributed to specific genes (Loth and others 2014). Globally, the most **common** reason for a low post-bronchodilator  $FEV_1:FVC$  ratio is smoking. Smoking in adolescence prevents the  $FEV_1$  developing to its full potential (Jaakkola and others 1991); continuing smokers have a dose-related decline in  $FEV_1$  of over 10 mL/yr greater

than in never smokers, ex-smokers or quitters (Lee PN and Fry JS. Systematic review of the evidence relating FEV<sub>1</sub> decline to giving up smoking. BMC Medicine 2010, 8:84). The decline in lung function returns to normal rates on cessation of smoking, but the FEV<sub>1</sub> does not recover more than about 200mL (Dockery and others 1988). Passive smoking is also associated with loss of FEV<sub>1</sub>:FVC ratio (Hooper and others 2012). **Figure \_\_.1.** shows the prevalence of a low FEV<sub>1</sub>:FVC ratio in the BOLD study, defined as below the lower limit of normal for men and women plotted against the mean pack years of cigarettes smoked (Burney and others 2014). There is a strong association between the two measures, as well as between it and the prevalence of ratios below the lower limit of normal. Where smoking is rare the prevalence of a low FEV: FVC ratio is close to 5 percent, the value expected by definition in a “normal” population without known respiratory disease.

**Figure 1. Prevalence of a low FEV<sub>1</sub>/FVC ratio (below the lower limit of normal) in the BOLD Study plotted against the mean pack years smoked in each centre.**

***(Insert figure after permission is obtained)***

Source: Burney et al. 2014

Other associations with chronic airway obstruction include a history of tuberculosis (Allwood and others 2013), occupational exposures to dust, a low body mass index, and age (Hooper and others 2012). The association between a history of tuberculosis and airway obstruction is more pronounced than its association with restrictive spirometry (low FVC) (Hooper and others 2012; Hwang and others 2014; Lam and others 2010; Menezes and others 2007). Studies have found a protective effect on lung function from a healthy diet, characterized by a high intake of fibre, fruits, and vegetables, and a low intake of simple sugars and saturated fats (Root and others 2014; Shaheen and others 2001). An adverse effect of processed meats has also been described (Varraso and others 2007). There is an association with age after adjustment of lung function for age and for years smoking (Hooper and others 2012). Because the evidence of an association with age comes largely from cross-sectional studies, there are two possible explanations: another environmental risk that is associated with cumulative reduction in FEV<sub>1</sub>, and an effect associated with year of birth rather than with age, a birth-cohort effect. The latter effect implies the appearance of a risk factor in early life that has a persistent effect over the life course and that may affect succeeding generations differently.

Two risk factors commonly associated with obstruction are air pollution, particularly indoor air pollution, and occupational exposures, but evidence that these are important risk factors is less convincing. These risk factors are associated with increased symptoms of bronchitis and in the frequency of acute exacerbations (lung attacks), and even of effects on mortality when life-time exposures are considered (Hansell A, Ghosh RE, Blangiardo M, Perkins C, Vienneau D, Goffe K, Briggs D, Gulliver J. Historic air pollution exposure and long-term mortality risks in England and Wales: prospective longitudinal cohort study. Thorax 2016;71:330–338.) but evidence of an effect on the FEV<sub>1</sub>:FVC ratio has been less consistent, at least in studies of the general population (Hooper and others 2012; Schikowski and others 2014; Smith and others 2014). It has, however, been argued

that there is a coherence in the evidence relating to different sources of particulate pollution, cigarette smoking, indoor sources, and outdoor sources that suggests that all of these factors play a part (Burnett and others 2014).

## Idiopathic Low FVC

A low FEV<sub>1</sub> is associated with several comorbidities and an increase in overall mortality. This condition represents an association with a low Total Lung Capacity (Pedone and others 2012) and a low FVC (Burney and Hooper 2011; Fried and others 1998; Kannel and others 1980;) and not with airflow obstruction. In clinical medicine, a low FVC is generally associated with specific restrictive lung diseases associated with fibrosis, which are relatively rare. A low FVC, however, is common, particularly in poor populations, and rates are rising rapidly in countries where the annual gross national income per capita is less than US\$15,000. Figure \_\_.2 shows the prevalence of a low FVC (below the lower limit of normal in the United States National Health and Nutrition Examination Survey white population (Hankinson, Odencrantz, and Fedan 1999), plotted against the gross national income per capita (Burney and others 2014a).

A similar pattern (figure \_\_.3) is seen for the distribution of mortality from COPD, suggesting that this is strongly associated with death attributed to this condition. It seems that high mortality rates attributed to COPD are more strongly associated with low lung volumes (FVC) than with obstruction (a low FEV<sub>1</sub>/FVC ratio). This observation fits with the evidence on survival among people with a low FEV<sub>1</sub>:FVC, which is more or less normal, when adjusted for the other effects of cigarette smoking, whereas people with a low FVC have a poor survival rate (Burney and Hooper 2011). Historically, the association between low lung volumes and mortality also fits with the association between social class and death from COPD in high-income countries (HICs), where the gradient across social classes has been even greater than that for tuberculosis, and far greater than that for lung cancer (Office of Population Censuses and Surveys, 1986) another condition strongly associated with cigarette smoking.

### **Figure \_\_.2 Prevalence of a Spirometric Restriction (FVC < LLN) Annual Per Capita Gross National Income**

***(Insert figure after permission is obtained)***

*Source:* Reproduced from Burney, Jithoo, and others 2014.

*Note:* FVC = forced vital capacity; LLN = lower limit of normal; PPP = purchasing power parity.

### **Figure \_\_.3 Age Standardized National Chronic Obstructive Pulmonary Disease (COPD) Mortality (Ages 15+ Years), by Gender and Annual Per Capita Gross National Income**

**(Insert figure after permission is obtained)**

Source: Burney and others 2014.

Note: LLN= lower limit of normal; PPP = purchasing power parity.

The risk factors for a low FVC, apart from poverty, are not well established. A consistent association has been made with low birth weight, confirming that this is at least in part a developmental condition determined early in life ((Barker and others 1991; Lawlor, Ebrahim, and Davey 2005). Nutrition might also play a role. In one study, children randomized to receive vitamin A in early life had a higher FVC than those randomized to placebo (Checkley and others 2010); a finding that may be relevant in populations with a low intake of vitamin A. A second randomized trial used a much lower dose of vitamin A as part of a multivitamin supplement during pregnancy. No effect on lung function was seen at age eight years (Devakumar and others 2015). There has been some evidence for a lower FVC in those exposed to higher levels of air pollution early in life (Schultz E, et al., 2016) but the evidence has been inconsistent. (Fuertes E, et al., 2015) Though the evidence is so far inconclusive ongoing trials reducing exposure to high levels of particulate pollution in children in low income settings will be important. Other risk factors for low FVC are even more speculative, but any factors associated with low birth weight could, in theory, also be important.

The influence of ethnicity or race upon FVC has been a topic of debate. African Americans have a lower FVC compared to white Americans of the same age, gender, and height (Hankinson, Odenchantz, and Fedan 1999). This is also true for African, Caribbean, and other ethnic minorities in the United Kingdom ((Hooper and Burney 2013) and for Aboriginal Australians (Cooksley and others 2015). However, the common assumption that this is explained by race alone is unwarranted at this time (Lundy, Wolfgang, and Dickersin 2013) for two reasons. First, ethnic minorities in all countries have poorer backgrounds, and since social deprivation has been strongly associated with a low FVC, this is a potential confounder (Menezes and others 2015; Sonnappa and others 2015). Second, the mortality for persons with a given FVC, age, height, and gender is the same irrespective of ethnicity, at least in the United States (Burney and Hooper 2012). This finding suggests that whether the origins are genetic or environmental, the effects are similarly detrimental (Burney and Hooper 2012).

### **Restrictive Lung Disease and Fibrosis**

Reduced maximal lung inflation (restriction) can be caused by chest wall stiffness, respiratory muscle weakness, or one of the many causes of widespread disease of the lung parenchyma that may result in diffuse lung scarring, called *fibrosis*. These diseases are collectively referred to as *diffuse*

*parenchymal lung disease* (Antoniou and others 2015). They are relatively uncommon and are further classified into those of known and unknown causes. Known causes include those caused by exposure to known fibrosing agents like inorganic dusts or organic dusts. Unknown causes include sarcoidosis and idiopathic pulmonary fibrosis (IPF) (Antoniou and others 2015); IPF is the most common. Best estimates of mortality from IPF are five to 10 cases per 100,000 population (age-standardized), and its prevalence appears to be increasing (Hutchinson and others 2014). Adding the occupational causes, or those secondary to systemic disease, may increase the prevalence of diffuse parenchymal fibrotic lung disease two to three times (Behr 2009). IPF has a relentless course until death ensues in three to five years, often from acute exacerbation (Travis and others 2013).

The clinical presentation of fibrosing lung diseases is shortness of breath and widespread inspiratory crackles in the lung bases that become more widespread as disease progresses. The chest roentgenogram usually shows diffuse nodular, or linear, opacities of varying size and combinations, depending on the cause; lung function testing shows reduced lung volumes and, in more advanced cases, impairment of gas exchange (respiratory failure). Finger clubbing is a common sign in established disease. Patients presenting with these features require referral as the diagnosis may require specialized procedures and even lung biopsies. High-resolution CT scans of the chest (HRCT) provide useful information and may be sufficient to confirm the diagnosis of IPF in cases in which other clinical features (including history) suggest this diagnosis. Lung biopsies are obtained through a limited thoracotomy or using minimally invasive thoracoscopic methods (Aziz and others 2004; Travis and others 2013). In some cases, biopsies can be avoided; the diagnosis can be confirmed by bronchoscopic means through the combined use of bronchoalveolar lavage (washings from bronchi), which may provide confirmatory evidence of lung malignancy, hemorrhage into lung tissue, an eosinophilic lung condition, or a chronic infection such as tuberculosis. Transbronchial or endobronchial biopsies are useful when sarcoidosis, an organizing pneumonia, or hypersensitivity pneumonitis is suspected to be IPF. Since the treatments for these different conditions vary widely, definitive diagnosis, sometime by exclusion, is essential.

Hypersensitivity pneumonitis (HP) usually has a benign course, especially with antigen avoidance. Corticosteroids are recommended for severely symptomatic patients with important functional and radiologic abnormalities. In some patients, however, especially those with bird-fancier's or pigeon breeder's lung, the prognosis is worse; some individuals develop severe and progressive fibrosis and cor pulmonale (Glazer 2015).

Lung fibrosis secondary to rheumatic diseases, for which blood tests are usually confirmatory, has a slightly better prognosis than IPF, but its presence worsens the prognosis in these diseases.

## Chronic Bronchitis and Bronchiectasis

Chronic bronchitis is defined as chronic cough, usually occurring in the winter months, that lasts for 3 months or more, that occurs in two successive years, and is associated with the production of phlegm. Acute exacerbations of COPD are more common in patients with chronic bronchitis, and these are commonly associated with bacterial infections in the bronchi. (GOLD 2014). Since exacerbations are thought to lead to more rapid loss of lung function and progression of COPD, preventing them is an important goal of COPD management (Vestbo and Hogg 2006).



It should be noted however that the symptoms of chronic bronchitis are non-specific, meaning that other lung conditions, and particularly asthma and bronchiectasis (discussed below), may present with similar symptoms. Inhalation of irritants in outdoor and indoor air pollution (Holland and Reid 1965), (Jindal and others 2006; Erlich and others 2004), and in the workplace may also produce similar symptoms. (Blanc and Toren 2007; Erlich and others 2004). There is little evidence that chronic bronchitis unassociated with advanced COPD is associated with increased mortality. (Peto et al. 1983.)

In bronchiectasis, increased sputum production is commonly associated by chronic bacterial colonization of the abnormal airways by one or more varieties of pathogenic organism. Infective flare-ups are common, often as a result of the appearance of more virulent organisms, and are marked by an increase in the volume or change in the color of sputum, with or without systemic features of infection, such as malaise and a temperature. The pathology in bronchiectasis involves local thinning and weakening of the bronchial wall, leading to areas of dilatation. In addition, the chronic infection leads to scarring of bronchi beyond the dilated areas that may cause airflow obstruction resembling COPD. In addition, weakened collapsible bronchi and damage to the lining of bronchi result in ineffective cough and clearance of secretions, favouring persistence and recurrence of infections. Bronchiectasis has become less common in HICs but remains common in LMICs, because of the continuing burden of infectious diseases and lung infections—tuberculosis, HIV, pertussis, measles, and adenoviral infections—particularly those occurring in childhood. Other factors, such as malnutrition, that compromise the immune system, also play a role (Chalmers, Aliberti, and Blasi, 2015)

## Primary Prevention of Chronic Lung Diseases

The strong association between respiratory mortality and socio-economic conditions strongly suggests that poverty reduction will lead to a lowering of the burden from respiratory disease, (Burney P, Patel J, Newson R, Minelli C, Naghavi M. Global and regional trends in COPD mortality, 1990–2010. *Eur Respir J* 2015; 45: 1239–1247) though the mechanisms are unknown. The most important specific measure for primary prevention of COPD is smoking cessation, including the reduction of exposure to environmental tobacco smoke, addressed in [\\_\\_ <<cross-reference will be added>>.](#) Improved prevention and management of tuberculosis is also likely to reduce the prevalence of chronic airway obstruction significantly in some regions, as well as to improve work environments. Other preventive measures for airflow obstruction are less well established; the use of cleaner fuels or improved biomass stoves is expected to reduce at least the symptoms of chronic respiratory diseases.

There is little evidence on the causes of low lung volume (low FVC), or on how this may be prevented. It is reasonable to speculate that improving birth weights through dietary measures and supplements for mothers or children (or both) might be beneficial. Encouraging mothers not to smoke during pregnancy might also be effective. Current large scale trials of the reduction of biomass exposure will quantify the benefits to be derived from this.

The primary prevention of chronic bronchitis also involves reducing the use of tobacco products and exposure to air pollutants. For bronchiectasis, the main strategy is preventing the spread of infection

either by prophylactic treatment (for HIV in newborns) or immunization against tuberculosis (BCG), measles, and pertussis, in combination with adequate and prompt treatment of infections. Annual Influenza and five-yearly polyvalent pneumococcal vaccination may reduce serious morbidity in those at risk of pneumonia, including elderly persons and those with chronic heart, lung, renal, or liver disease. The role of smoking in increasing the risk of most pulmonary infections, including tuberculosis, provides further grounds for public health measures to target this addiction.

## Principles of Care

The aims of disease management of patients with chronic respiratory disease vary according to the nature and stage of the disease. Principal objectives in all cases are early detection to limit the progression and severity of disease, and implementation of secondary preventive measures. Early identification of persons susceptible to the effects of harmful exposures permits a more targeted approach to risk reduction and may be relevant to their family members, for example, by identifying those with rare genetic conditions that render them susceptible to developing emphysema. At risk persons need to be given clear instructions on how to avoid potentially harmful smoke and other pollutants.

Proposed treatments need to be evaluated in terms of efficacy, acceptability, effectiveness, value for money, and scalability (box 1). The attributes of an intervention or treatment are not necessarily the same in all environments; most research on the treatment of lung diseases has been performed in HICs, and recommendations may not be applicable in other settings. Nevertheless, the evidence from HICs may be the only evidence available.

## Management of chronic lung diseases

Every effort should be made to reduce all harmful exposures linked to any respiratory disease: tobacco, occupational dusts, indoor and outdoor pollution, and tobacco use.

### Asthma

Despite the development of many regional and international asthma guidelines that have reduced the burden of disease and death in most countries (Haahtela and others 2006), the level of asthma control is poor in a large proportion of patients in other regions (Ayuk and others 2014; Masoli and others 2004; Price, Fletcher, and van der Molen 2014; Vietri, Burslem, and Su 2014; Zemedkun, Woldemichael, and Tefera 2014). The success in reducing asthma-related death rates in HICs has highlighted the disparity with LMICs.

### Diagnosis

Asthma as a heterogeneous disease, usually characterized by chronic airway inflammation and its diagnosis involves recognition of characteristic symptoms of respiratory periodic airflow obstruction. The Global Initiative for Asthma (GINA) recommends that the clinical diagnosis should in all cases be confirmed by measurements of reversible airflow at some time, either in the past or currently. Characteristic symptoms, are wheeze, shortness of breath, chest tightness, and cough, that vary over time and in intensity and are relieved, at least partially, but use of a rapid-acting inhaled bronchodilator (1). Heterogeneity refers to the varying patterns of disease with respect to onset, time course (Martinez and others 1995), associations with allergic diseases and severity (Boudier and

others 2013). This heterogeneity has important implications for selection of treatment, particularly in severe asthma.

A multi-dimensional view of asthma that aids diagnosis, assessment, and therapy has been proposed (Gibson, McDonald, and Marks 2013). This multi-dimensionality includes airway pathology, symptoms, lung function abnormalities, body mass and nutrition, gas exchange abnormalities, exercise capacity, and comorbidity. Other features that may be present are variability of symptoms from day to day and from season to season, onset during early childhood, almost immediate relief from the use of a short-acting bronchodilator, and periods when symptoms disappear, particularly if these are associated with a trial of inhaled corticosteroids.

Airflow limitation is demonstrated by the use of peak flow meters or spirometers, which measure airflow during forced expiration either as Peak Expiratory Flow (PEF) or Forced Expiratory Volume in one second (FEV<sub>1</sub>) (GINA 2014). These are compared with predicted value for the patient's gender, age, and height. Measurements taken before and after a dose (four puffs are recommended) of a short-acting beta<sub>2</sub>-agonist confirms reversible airflow limitation, which should be interpreted in the context of the syndromic diagnosis. The pathology of asthma in most cases involves hyperresponsiveness of airway smooth muscle and bronchospasm. Several other respiratory conditions may present with some of these features, and these conditions vary according to patient age. The use of alternative diagnostic terms like *recurrent bronchitis* or *wheezy bronchitis* may delay diagnosis and appropriate treatment (Speight, Lee, and Hey 1983).

## Assessment

The proper management of the disease involves assessing both day-to-day control (also called *impairment*), and the likelihood of longer-term problems, including asthma exacerbations (also referred to as *risk*) (GINA 2014; National Asthma Education and Prevention Program 2007).

- The assessment of current control is based on the presence and frequency each week of daytime and night time symptoms of asthma, activity limitation, use of rescue inhalers, and FEV<sub>1</sub> (or PEF). These are combined in a single score, and the asthma is described as controlled, partly controlled, or uncontrolled.
- Risk or future risk includes the frequency of asthma exacerbations, chronic impairment of lung function (fixed airflow limitation), and side effects of harmful treatment, particularly those caused by the chronic use of oral or systemic corticosteroids commonly used in LMICs.

There has been intense research interest in finding simple and accurate ways of measuring predictors of response to therapy to assist in targeting therapy most appropriately, as well as response to therapy to evaluate success. Measurement of the fraction of nitric oxide in exhaled breath (Powell and others 2011), sputum (Siva and others 2007), and blood eosinophils (Bafadhel and others 2012) are the most promising at present.

Further implementation research on biomarker-based targeted approaches to therapy for asthma is ongoing. The limited availability and high cost of these tests and of the targeted treatments will restrict their use, even in severe asthma (Chung and others 2014). Biomarkers have limited value in diagnosing asthma in routine practice, but they are used in specialized centers. The great majority of patients with asthma is adequately diagnosed and managed using predominantly symptom-based clinical algorithms that target asthma control alone (GINA 2014).

## Pharmacological Management

Control-based asthma management, as recommended in the GINA guidelines, is a stepwise approach in which treatment is escalated and de-escalated to find the least treatment intensity that maintains good control. Good asthma control is defined as infrequent symptoms or need for short-acting beta<sub>2</sub>-agonist during the day and at night, the absence of exacerbations, and normal or near normal lung function, if measured.

The treatment steps are as follows:

- Short-acting beta<sub>2</sub>-agonist taken as required for symptoms
- Regular (once or twice daily) low-dose inhaled corticosteroid OR leukotriene receptor antagonists with short-acting beta<sub>2</sub>-agonist taken as required for symptoms;
  1. Either
    - a. Regular (once or twice daily) low-dose inhaled corticosteroid long-acting beta<sub>2</sub>-agonist combination therapy with short-acting beta<sub>2</sub>-agonist as required for symptoms
    - b. Low-dose inhaled corticosteroid/formoterol (a rapid onset long-acting beta<sub>2</sub> agonist) combination therapy taken twice daily and as needed, or
    - c. Regular (once or twice daily) medium-high dose inhaled corticosteroid in conjunction with short-acting beta<sub>2</sub>-agonist, as required, for symptoms
  2. Either
    - a. Regular (once or twice daily) medium/high dose inhaled corticosteroid: long-acting beta<sub>2</sub>-agonist combination therapy together with short-acting beta<sub>2</sub>-agonist, as required, for symptoms, or
    - b. Low-dose inhaled corticosteroid/formoterol combination therapy twice daily and as required for symptoms
  3. Step 2, plus add-on therapy, which may include tiotropium (a long-acting inhaled anti-cholinergic, previously only used in COPD), oral corticosteroids, anti-IgE therapy, or other newer targeted biologicals.

Additional measures recommended before escalating treatment are the following:

- Check both adherence and inhaler technique
- Treat or avoid modifiable risk or exacerbating factors
- Manage any side effects of treatment.

Long-acting beta<sub>2</sub>-agonist therapy should never be used without inhaled corticosteroid in patients with asthma; this mode of treatment has been associated with increased risk of death (Durham and others 1999). Only inhaled corticosteroid alone or inhaled corticosteroid/long-acting beta<sub>2</sub>-agonist combination inhalers should be prescribed for patients with asthma (USFDA 2010). Relatively low-cost generic versions of all these classes of drugs are available.

### Barriers to Treatment

The efficacy and safety of inhaled corticosteroids in the management of patients with asthma is well-established (Adams, Bestall, and Jones 2009; Adams, Bestall, Lasserson, and others 2009; Adams, Bestall, Malouf, and others 2009). The use of inhaled corticosteroids is associated with reduced risk of asthma-related death (Suissa and others 2000).

However, many barriers to effective implementation of treatment result in suboptimal outcomes. The most important barrier is patient non-adherence to controller treatments, a factor shared with other chronic diseases that require regular daily treatment. Other barriers include delayed diagnosis, ineffective patient education, poor inhaler technique, low expectations of control, and lack of appreciation of inadequate control by physicians and patients. Other barriers are cultural values, preferences, and priorities. The most significant barrier in LMICs is access to inhaled corticosteroids, usually because of the non-affordability of medication (GINA 2014). The ratio of inhaled corticosteroid to rescue inhaler use (bronchodilator) has a strong inverse correlation with hospitalizations for asthma attacks and asthma mortality. The higher the population coverage with ICS is, the lower the asthma morbidity (Phui, Tan, and Lim 2008).

Health system barriers include poor training of health care workers, lack of availability of quality controlled products, and lack of affordability (Ait-Khaled and others 2000). If good quality medication is locally available and affordable, the major barrier is the need for patients to take this medication using either inhaled dry powder or pressurized inhalers with spacers. Poor inhalation technique reduces the efficacy of the medication; poor adherence results in suboptimal control of the disease.

In general, regular follow-up by health care workers may represent the most cost-effective way to improve adherence and ensure correct inhaler techniques. The Finnish asthma program has shown that a community approach in setting up a network of support for practitioners may be a very cost-effective way to improve asthma control in the community (Erhola and others 2003; GINA 2014; Haahtela and others 2001; Haahtela and others 2006; Kauppi and others 2013).

Many asthma educational programs have been developed by national health agencies, such as the Finnish Asthma Program, by individual hospitals, and by patient organizations and nongovernmental organizations. There is no doubt that a combined effort in the diagnosis, early use, and easy access to anti-inflammatory therapy, with periodic assessment of asthma control, will reduce asthma-related morbidity and mortality. Despite the best care, however, approximately 5 to 10 percent of patients still have significant symptomatic asthma. Alternative approaches to managing these patients, who are responsible for a substantial burden of costs and poor outcomes, are required (Bousquet and others 2010; Chung and others 2014).

## Chronic Obstructive Pulmonary Disease.

### Diagnosis

COPD typically presents in a person over age 40 years with breathlessness on exertion that is persistent and progressive. Wheezing and chest tightness and an intermittent or persistent cough that may be associated with the production of sputum may also be present (GOLD 2014).

Exacerbations, that is, episodes of worsening of symptoms (breathlessness, cough, or sputum production) beyond the normal day-to-day variation are an important feature of the history of CAO. The diagnosis is confirmed by spirometry as described, and is defined as a one-second forced expiratory volume ( $FEV_1$ ) as a percent of the Forced Vital Capacity (FVC) below the lower limit of normal following inhalation of a short-acting bronchodilator. This definition of normal is specific to a given age, gender, and height; however, as almost all spirometers can be programmed to show the normal value, the lower limit of normal should be used to define the presence of an abnormality rather than the fixed cut off of 70 percent.

Not all primary care facilities have access to spirometry, and a peak flow meter can be used to exclude the diagnosis with reasonable accuracy. Moderate obstruction is unlikely if the pre-bronchodilator PEFr is over 2.2 L/sec/m<sup>2</sup>; severe disease is unlikely if the PEFr is above 1.8 L/sec/m<sup>2</sup> post-bronchodilator or 1.3 L/sec/m<sup>2</sup> pre-bronchodilator (Jithoo and others 2013).

Peak flow meters are inexpensive and should be widely available. Spirometers are more expensive, but inexpensive spirometers need to be affordable for secondary care. The main limitation on their use is lack of training in the use and interpretation of findings.

Clinical course and management.

Patients with COPD generally experience a slow but progressive cycle of worsening exertional dyspnea, which leads to lack of exercise and muscle deconditioning and reduces both work capacity and quality of life. Exercise programs can to some extent slow this cycle, improve effort tolerance and relieve dyspnea and fatigue and improve quality of life (Lacasse and others 2006). Such programs do not need to be expensive or complex; they are best incorporated into a lifestyle of regular exercise four or more times a week, involving both endurance and muscle strengthening (Ipsen and others 2015). A simple physical activity enhancement program using pedometers can effectively improve physical activity level and quality of life in COPD patients in low-resource settings (Mendoza and others 2015). Aerobic exercise training also reduces disease exacerbations (Güell and others 2000).

Some patients with severe COPD, but not necessarily in respiratory failure, lose body weight. This weight loss is not entirely explained by reduced dietary intake and relates to the systemic effects of chronic lung disease and to deconditioning and loss of muscle mass. This process has an impact on functional ability and quality of life and is associated with increased mortality. Nutritional supplements, coupled with an exercise program, can improve but not reverse, this process; they can increase body weight, respiratory muscle strength, walking ability, and quality of life (Ferreira and others 2009). Anabolic steroids have no lasting effect (Pan and others 2014).

For hypoxemic patients with COPD, the long-term use of supplemental oxygen improves survival (Medical Research Council 1981) and may improve quality of life (Eaton and others 2002). Long-term outpatient oxygen therapy at a flow rate determined by measurement of blood oxygen saturation may possibly delay the onset of pulmonary hypertension. Its benefit for chronic pulmonary diseases other than COPD has not been demonstrated (Jindal 2012). This therapy should be used for a minimum of 12 hours per day, and it is usually restricted to patients with COPD who have stopped smoking. Ambulatory oxygen therapy, even if it does not improve survival, facilitates independence, lessens restrictions of physical and social activities, and improves quality of life.

Annual influenza vaccination reduces the incidence of exacerbations, particularly those due to influenza virus, and is recommended for patients with COPD (Poole and others 2006). Although it is not effective against the majority of viruses that cause upper respiratory tract infections (URTIs), vaccination may reduce morbidity and mortality in these susceptible patients during the annual influenza season. Most of the exacerbations of asthma, especially in children, and COPD are precipitated by a viral URTI and are accompanied by secondary bacterial bronchial infection. Rhinoviruses are the most common viruses responsible for these events for which no vaccine is available; antibiotics are indicated for the bacterial component and when purulent sputum becomes

evident (Poole and others 2006). Pneumococcal vaccines are effective in preventing the more severe forms of infection caused by the pneumococcus organism, the most important cause of pneumonia in patients of all ages (Walters and others 2010). Five-yearly administration of polyvalent pneumococcal vaccine is advised for patients with chronic lung disease (Walters and others 2010).

Common comorbid conditions, including heart disease, diabetes, cancer, lower respiratory tract infections, musculo-skeletal conditions, and psychiatric disorders, should be treated or controlled to improve outcomes in patients with chronic respiratory disease (Gershon and others 2015).

### **Pharmacological Management of Stable Disease**

Most patients with COPD respond to inhaled short-acting bronchodilators; these are the firstline of treatment for symptomatic disease and provide some temporary symptom relief in most people. Two pharmacological classes of short-acting bronchodilators are available: beta<sub>2</sub>agonists (SABA) and anti-muscarinics (SAMA). Neither class has a clear advantage (Chong, Karner, and Poole 2012). They may be given either alone or in combination; combination inhalers containing both are available. They are generally administered for use as needed; if symptoms are more persistent, they are administered for use every four to six hours. Their duration of action is less than six hours, which explains their failure to improve patients' quality of life or prevent COPD exacerbations.

Inhaled long-acting beta<sub>2</sub>agonists (LABA) (Kew, Mavergames, and Walters 2013)(2) or long-acting muscarinic antagonists (LAMA) (Karner, Chong, and Poole 2013) are taken once or twice daily and provide sustained bronchodilation. They are recommended for patients with persistent daily symptoms that limit activity, especially those who have experienced at least one COPD exacerbation in the past year. Used alone or in combination, they have been shown to result in sustained bronchodilation, improved symptoms and quality of life, reduced activity limitation, facilitated rehabilitation programs, and reduced exacerbations. A SABA or SAMA is usually provided for as-needed use. Long-acting formulations are generally well tolerated and are recommended when symptoms are not adequately controlled with inhaled short acting beta<sub>2</sub>agonists.

Short-acting bronchodilators, taken regularly or as required, are cheaper and more widely available; long-acting bronchodilators, taken once or twice daily, are generally more convenient and provide more sustained benefit (Global Initiative 2014). The United States Food and Drug Administration has expressed concern about the occurrence of severe exacerbations by some patients using long-acting beta<sub>2</sub>agonists (USFDA 2010). This concern seems to be limited to patients who take this class of medication without inhaled corticosteroids.

Oral beta<sub>2</sub>agonists and oral theophylline are cheaper alternatives to inhaled bronchodilators. However, they have more systemic side effects and are less effective than inhaled medications. Accordingly, they are not recommended.

The use of inhaled corticosteroids in patients with COPD is controversial. Although these agents are not as effective as in asthma, they do reduce the frequency of exacerbations in people with a history of frequent exacerbations; they also reduce the rate of decline in quality of life (Yang and others 2012). They have not been shown to have any effect on decline in lung function or mortality (Global Initiative 2014). Their use in COPD has been associated with an increased risk of pneumonia, leading to caution except when specifically indicated (Suissa and others 2013). High doses are contraindicated because the risk of pneumonia is dose-related. Other side effects include

candidiasis, skin bruising, cataracts, and possibly reactivation of previous pulmonary tuberculosis. The role of inhaled corticosteroids in the management of COPD is limited to those with severe disease and frequent disease exacerbations.

Several combination inhaler devices are available that contain either two long-acting bronchodilators (beta<sub>2</sub>-adrenergic agonists and muscarinic antagonists) or a long-acting bronchodilator and an inhaled steroid. The effect of these combination inhalers is probably similar to that of the addition of their individual components, but a single inhaler is generally more convenient and may lead to enhanced adherence to treatment regimens.

Evidence about the effectiveness of long-term oral corticosteroids in people with stable CAO is lacking. Their adverse effects, including myopathy, are well established; they are probably best avoided, if possible, or otherwise administered in the smallest possible dose.

### **Management of Exacerbations**

First-line management of exacerbations of COPD includes the use of repeated inhaled beta<sub>2</sub>agonists by the most efficient route, supplemental oxygen if the patient is hypoxemic (the presence of cyanosis, preferably confirmed by oximeter), and either oral corticosteroids and antibiotics, or both. Administration of systemic corticosteroids to patients presenting with acute exacerbations of COPD (usually oral) reduces the risk of treatment failure and of early relapse, causes more rapid improvement in lung function (FEV<sub>1</sub>), and is associated with a shorter length of hospital stay (Walters and others 2014). However, it is also associated with an increased risk of adverse effects (Walters and others 2014). Administration of antibiotics to patients with acute exacerbations of COPD probably reduces the risk of treatment failure; the evidence is strongest for people with severe exacerbations requiring hospitalization (Vollenweider and others 2012).

Supplemental oxygen therapy should be administered to patients with acute exacerbations of COPD who are hypoxemic with low flow (1-2 litres per minute) oxygen administered via nasal cannulae. In patients with acute or acute on chronic respiratory failure (low blood oxygen content) due to an acute exacerbation of COPD, the administration of non-invasive positive pressure ventilation (NIPPV, also known as *bi-level positive airway pressure*, *BiPAP*) via a nasal or face mask, reduces length of hospital stay, avoids the need for intubation and invasive mechanical ventilation, and may improve survival (Ram and others 2009).

Self-management with prescription of drugs to be taken in the event of a subsequent exacerbation reduces the delay in commencing treatment and may reduce the risk of hospitalization. Active rehabilitation following hospitalization reduces mortality and re-hospitalisation. Methylxanthines are not recommended (GOLD 2014).

### **Idiopathic Low FVC**

There is no recognized treatment for patients with idiopathic low FVC, but careful assessment should be made for comorbidities, including diabetes and cardiovascular disease. Treatment options may be available for patients with a low FVC associated with the conditions identified in the next section.



## Restrictive and Fibrosing Lung Diseases

### Diagnosis

The diagnosis of interstitial lung diseases is generally made following referral to specialists. However, the diagnosis is frequently delayed for several months, and patients are misdiagnosed and wrongly treated for congestive cardiac failure, pneumonia, asthma, COPD, or tuberculosis. The most important clues to the correct diagnosis are a typical chest roentgenogram and the presence of inspiratory crackles and clubbing.

Owing to their rarity, no strategy for screening in the general population is warranted, except in populations with a higher risk of developing specific forms of fibrosing lung diseases—such as workers exposed to inhaled agents (fibrogenic dusts such as asbestos or silica, or a variety of organic antigens). These categories of worker should be reviewed periodically by radiography with or without spirometric studies. Patients with rheumatoid arthritis, scleroderma, systemic lupus erythematosus, mixed connective tissue disease, and dermatomyositis/polymyositis are also at risk of developing, and their respiratory status should be regularly reviewed by their physicians. Lung involvement in these diseases often dominates the clinical course of the disease and may be fatal.

### Treatment

General support measures are appropriate. Reducing or avoiding further exposure to the offending agents in secondary fibrotic lung disease, such as hypersensitivity pneumonitis or pneumoconiosis, is important. The presence of gastroesophageal reflux should be considered in all patients, appropriate investigations performed and, if present, the condition should be treated. The presence of gastroesophageal reflux leads to faster deterioration in lung function and produces more respiratory symptoms (Raghu 2013). Effective treatment of gastroesophageal reflux is possible even in low-resource settings.

No treatment for IPF has improved survival or quality of life sufficiently to be recommended widely in individuals with active and progressive disease. Several drugs and combinations of drugs, predominantly immunosuppressants and corticosteroids, have been used unsuccessfully to treat IPF (Davies, Richeldi, and Walters 2003; Richeldi 2012). Although Pirfenidone has not demonstrated a reduction in mortality, it may slow the decline in lung function (forced vital capacity, DL<sub>CO</sub> or six-minute walking distance) (Azuma and others 2005; Noble and others 2011; Spagnolo and others 2010; Taniguchi and others 2010). However, its use is associated with significant side effects (Jiang and others 2012). Other drugs investigated in randomized controlled trials in IPF patients include co-trimoxazole (Shulgina and others 2013), sildenafil (preserves exercise capacity in patients with right-ventricular hypertrophy or systolic dysfunction (Han and others 2013); and high-dose tyrosine-kinase inhibitor (BIBF-1120) (Richeldi and others 2011). Confirmation of these findings in other trials is awaited. The more specialized medications are unlikely to be widely available in low-resource settings or outside of third-level facilities.

Exacerbations of IPF have many causes, such as pulmonary thromboembolism, respiratory infection, and heart failure; an idiopathic acute exacerbation has been described, consisting of diffuse alveolar damage. In general, acute exacerbations of IPF are treated with antibiotics, systemic corticosteroids, and at times, immunosuppressive drugs, although the prognosis remains poor despite these measures (Agarwal and Jindal 2008).

Hypersensitivity pneumonitis (HP) (for example, Bird-fancier's or pigeon breeder's lung) generally responds to antigen avoidance, but corticosteroids are recommended for highly symptomatic patients with important functional and radiologic abnormalities. Some individuals develop severe fibrosis.

In patients with progressive systemic sclerosis with deteriorating lung function and HRCT abnormalities suggesting inflammation, a modest response to cyclophosphamide was found after one year of treatment, although with significant toxicity (Tashkin and others 2006). This benefit had largely waned at the second year of follow-up (Khanna and others 2007). Patients with progressive ILD in rheumatoid arthritis or systemic lupus erythematosus may warrant treatment with corticosteroids, with or without immunosuppressive drugs, although there is little evidence from clinical trials to support the use of this therapy.

Patients with advanced disease or those with the more aggressive idiopathic pulmonary fibrosis require evaluation for lung transplantation.

## **Bronchiectasis**

Evidence-based guidelines for the management of bronchiectasis have been prepared for HICs (Chang and others 2010; Hill and others 2011), but the quality of the available evidence is low. Management is directed to improving mucus clearance and preventing and treating infections to limit the long-term consequences of repeated episodes of LRTIs.

Limited evidence exists for non-pharmacological interventions. Inspiratory muscle training (Bradley, Moran, and Greenstone 2002) is moderately helpful; airway clearance techniques (Lee, Burge, and Holland 2013) are safe and improve quality of life. Moderate evidence supports the use of pneumococcal vaccine (Chang and others 2009) in chronic lung diseases, including bronchiectasis. However, no evidence is available to indicate that influenza vaccine is beneficial, but this lack may reflect the small size of studies (Chang, Morris, and Chang 2007).

Inhalation of nebulized mannitol increases the time between exacerbations (Hart and others 2014); mucolytics, such as acetylcysteine, that reduce the tenacity of sputum (Wilkinson and others 2014) may be helpful in conjunction with other therapies. Prolonged antibiotics, particularly macrolides, may be beneficial in reducing purulent sputum and preventing episodes of clinical infection, possibly through their effect on local defence mechanisms rather than their antibiotic properties. (Evans, Bara, and Greenstone 2007). Their long-term or even intermittent use is however, associated with the development of bacterial resistance to antibiotics, and/or colonisation of the bronchi with a sequence of more virulent treatment-sensitive organisms like *Moraxella catarrhalis* and Streptococcal strains, through Haemophilus influenza, then *Staphylococcus aureus*, and finally, less pathogenic but relatively treatment resistant organisms, such as *Pseudomonas aeruginosa*. This march of organisms can be reduced by judicious use of antibiotics and employing principles and regimens recommended for patients with cystic fibrosis (Chalmers, Aliberti, and Blasi 2015).

## **Systems and Organization of Care**

The system of care for patients with respiratory diseases is as important as the treatments. Chronic respiratory diseases are often overlooked or poorly managed in outmoded health systems that focus on treating exacerbations or acute events rather than rely on effective chronic care to prevent such

events. Similarly, a reliable source of continuing care and a clear management plan are as important as the correct diagnosis and initial treatment. The plan most appropriate for a given population varies according to the access to care and the available resources, but the principles are similar. Effective management programs for patients with chronic lung disease have increased the quality of life and exercise tolerance and reduced hospitalizations; the introduction of national programs have been associated with reduced hospitalization, drug costs, and disabilities associated with asthma (Haahtela, Tuomisto, and others 2006), as well as hospitalizations and disabilities associated with COPD (Pietinalho and others 2007). In LMICs, the Practical Approach to Lung health (PAL) has reduced prescribing costs per patient (Hamzaoui and Ottmani 2012).

Several key issues in planning health services warrant consideration:

- The importance of ensuring continuity of care, particularly with asthma, has been studied extensively and confirmed in HICs and LMICs.
- Integration ensures that the correct treatment is given at the lowest level that is capable of delivering it effectively and appropriately and that promptly refers patients to higher levels when appropriate. In most cases, staff members with basic training and adequate supervision can provide care for common conditions.
- Financing arrangements vary substantially; patients in poorer countries are more likely to bear the costs of treatment at the point of service. Financial constraints limit the services that can be offered, particularly for chronic diseases; methods of payment may pose separate barriers. Simple insurance schemes that are affordable, whether individual or financed through taxes or payroll levies, help to spread the costs across time and risk groups and make it more likely that uptake of services will be continuous; these schemes may reduce overall costs in the long run.
- Selecting appropriate treatments is inevitably a local decision. The affordable care packages and costs of treatments and of staff vary. The cost of importing medications may not vary greatly, but the availability of foreign exchange does.
- The purchasing and security of supply of medications is problematic in some LMICs. The costs are often higher, and the quality is often poor, a consequence of underdeveloped and unregulated markets. The provision of inhalers that have the correct specification for good penetration into the airway is technically difficult. If the supply chain does not deliver affordable and high-quality medications on a regular basis without repeated stockouts, effective management of these conditions is impossible.

The WHO programs of integrated care for adults can serve as a model for LMICs. An example is the Practical Approach to Lung Health (PAL) developed by the STOP TB Partnership, which includes care pathways for the diagnosis and management of asthma and COPD alongside those for screening and treating tuberculosis. The approach has been implemented and audited in many countries and has provided consistent benefits, even achieving cost savings for health systems. Another example is the Integrated Management of Adult and Adolescent Illness (IMAI), which describes care pathways for acute and chronic diseases, with a strong focus on integrating patient care with that for HIV/AIDS and tuberculosis. IMAI has been implemented in several countries, but its length and density of recommendations present barriers to its use in poorly resourced countries. However, it may serve as a useful resource for health departments seeking to develop locally applicable integrated models of care (WHO 2013a). A third example is the WHO Package of Essential Noncommunicable (PEN)

Disease interventions for primary health care, which includes evidence-based guidelines on diabetes, chronic respiratory disease, cancer, heart disease, and stroke. Pilot implementation projects are ongoing in several countries (WHO 2013b).

#### Box \_\_.2: CASE STUDY

## Conclusions

LMICs typically have a high burden of disease associated with chronic respiratory conditions, yet the information on which to formulate policy is negligible when compared with HICs. The lack of reliable information is compounded by generally poor infrastructure for commissioning, providing, and monitoring services and for training and supporting staff members.

Most of the deaths attributed to COPD occur in East and Southern Asia. These regions have very high age-specific mortality from the condition. Understanding the nature of the problem is only emerging with the completion of large-scale descriptive surveys with good quality spirometry. The descriptive epidemiology of chronic respiratory disease, nevertheless, remains sketchy in many areas of the world. What is becoming clear, however, is that they do not replicate findings in the more affluent regions.

Similarly, information on the efficacy and safety of different medications is largely drawn from studies in HICs. There is relatively little that specifically addresses the assessment of these medications in other populations. The lack of clarity on the safety of long-acting beta-agonists in some ethnic groups makes it difficult to optimize health care for these groups.

There is also inadequate infrastructure for effective implementation. Health services require a reliable and secure supply of diagnostic services, as well as medications and other treatments, to function well. Moreover, these elements need to be linked to well-supported staff members with the skills to deploy these services optimally. Although there is serious lack of appropriate research on the specific problems of low income countries, examples of effective primary care and tuberculosis control programmes in LMICs provide encouraging evidence that the quality of care – diagnosis, treatment and appropriate referral to higher levels of care – can be achieved through customized integrated programmes that educate, empower and support frontline clinicians, even in severely resource constrained settings, and more importantly, may prompt changes in policies and provision of resources necessary for managing these common but currently neglected chronic respiratory diseases.

## References

- Adams, N. P., J. C. Bestall, and P. Jones. 2009. Budesonide versus placebo for chronic asthma in children and adults. *Cochrane Database of Systematic Reviews* (4). [Q: Complete]
- Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. *Cochrane Database of Systematic Reviews* 2008, Issue 4. Art. No.: CD003135.
- Adams, N. P., J. C. Bestall, R. Malouf, T. J. Lasserson, and P. Jones. 2009. Beclomethasone versus placebo for chronic asthma. *Cochrane Database of Systematic Reviews* (1). [Q: Complete]
- Ait-Khaled, N., G. Auregan, N. Bencharif, L. Camara Mady, E. Dagli, and others. 2000. Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. *International Journal of Tuberculosis and Lung Disease* 4: 268-71.
- Allwood, B. W., L. Myer, and E. D. Bateman. 2013. A Systematic Review of the Association between Pulmonary Tuberculosis and the Development of Chronic Airflow Obstruction in Adults. *Respiration* 86 (1): 76-85.
- Antoniou, K. M. M., S. Tomassetti, F. Bonella, U. Costabel, and V. Poletti. 2015. Interstitial lung disease. *Eur Respir Rev.* 23 (40-54).
- Asher, M. I., P. K. Pattermore, A. C. Harrison, E. A. Mitchell, H. H. Rea, and others. 1998. International Comparison of the prevalence of asthma symptoms and bronchial hyperresponsiveness. *Amer Rev Respir Dis.* 138: 524-29.
- Agarwal, R., and S. K. Jindal. 2008. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. *European Journal of Internal Medicine* 19 (4): 227-35.
- Ayuk, A. C., T. Oguonu, A. N. Ikefuna, and B. C. Ibe. 2014. Asthma control and quality of life in school-age children in Enugu south east, Nigeria. *Nigerian Postgraduate Medical Journal* 21 (2): 160-64.
- Aziz, Z. A., A. U. Wells, D. M. Hansell, G. A. Bain, S. J. Copley, and others. 2004. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. *Thorax* 59 (6): 506-11.
- Bafadhel, M., S. McKenna, S. Terry, V. Mistry, M. Pancholi, and others. 2012. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. *Amer J of Respir Crit Care Med.* 186 (1): 48-55.
- Azuma, A., T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, and others. 2005. Double-blind, placebo-controlled trial of pirfenidone in patients with Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine* 171 (9): 1040-47.
- Barker, D. J. P., K. M. Godfrey, C. Fall, C. Osmond, P. D. Winter, and S. O. Shaheen. 1991. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. *BMJ* 303: 671-75.
- [Barton GR](#)<sup>1</sup>, L. Fairall , M.O. [Bachmann](#), K. Uebel, V. Timmerman, C. Lombard, and M. Zwarenstein. 2013. Cost-effectiveness of nurse-led versus doctor-led antiretroviral treatment in South Africa:

pragmatic cluster randomised trial. *Tropical Medicine & International Health* 18 (6): 769-77. doi:10.1111/tmi.12093. Epub March 11.

Behr, J. T. V. 2009. Update in diffuse parenchymal lung disease 2008. *Am J Respir Crit Care Med* 179: 439-44.

Boudier, A., I. Curjuric, X. Basagana, H. Hazgui, J. M. Anto, and others. 2013. Ten-Year Follow-up of Cluster-based Asthma Phenotypes in Adults: A Pooled Analysis of Three Cohorts. *Am J Respir Crit Care Med*. 188 (5): 550-60.

Blanc, P. D., and K. Torén. 2007. Occupation in chronic obstructive pulmonary disease and chronic bronchitis: an update. *Int J Tuberc Lung Dis* 11 (3):251-57.

Bousquet, J., E. Mantzouranis, A. A. Cruz, N. Ait-Khaled, C. E. Baena-Cagnani, and others. 2010. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. *J Allergy Clin Immunol* 126 (5): 926-38.

Bradley, J. M., F. Moran, and M. Greenstone. 2002. Physical training for bronchiectasis. *Cochrane Database of Systematic Reviews* 2. [Q: Complete]

Burnett RT, Pope CA 3rd, Ezzati M, Olives C, Lim SS, and others. 2014. An integrated risk function for estimating the global burden of disease attributable to ambient fine particulate matter exposure. *Environ Health Perspect*. 122: 397-403.

Burney, P. G. J., and R. Hooper. 2011. Forced vital capacity, airway obstruction and survival in a general population sample from the USA. *Thorax* 66 (1): 49-54.

Burney, P. G. J., and R. J. Hooper. 2012. The use of ethnically specific norms for ventilatory function in African-American and white populations. *Int J Epidemiol*. 41 (3): 782-90.

Burney P, Patel J, Newson R, Minelli C, Naghavi M. Global and regional trends in COPD mortality, 1990–2010. *Eur Respir J* 2015; 45: 1239–1247 Calvert J, Burney P. Effect of body mass on exercise induced bronchoconstriction and atopy in African children. *J Allergy Clin Immunol* 2005; 116 (4): 773-9

Chalmers, J. D., S. Aliberti, and F. Blasi. 2015. State of the art review: management of bronchiectasis in adults. *Eur Respir J*. 2015 May;45(5):1446-62

Chang, A. B., S. C. Bell, C. A. Byrnes, K. Grimwood, P. W. Holmes, and others. 2010. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation. *Med J Austr* 193 (6): 356-65.

Chang, C. C., P. S. Morris, and A. B. Chang. 2007. Influenza vaccine for children and adults with bronchiectasis. *Cochrane Database of Systematic Reviews* 3. [Q: Complete]

Chang, C. C., R. J. Singleton, P. S. Morris, and A. B. Chang. 2009. Pneumococcal vaccines for children and adults with bronchiectasis. *Cochrane Database of Systematic Reviews* 2. [Q: Complete]

Checkley, W., J. K. P. West, R. A. Wise, M. R. Baldwin, L. Wu, and others. 2010. Maternal Vitamin A supplementation and lung function in offspring. *New England Journal of Medicine* 362 (19): 1784-94.

Chinn, S., D. Jarvis, R. Melotti, C. Luczynska, Ackermann-Liebrich, and others. 2005. Smoking cessation, lung function, and weight gain: A follow-up study. *The Lancet* 365 (9471): 1629-35.

Chong, J., C. Karner, and P. Poole. 2012. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 9: CD009157.

Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, et al 2014. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J* 43: 343–73.

Cooksley, N. A., D. Atkinson, G. B. Marks, B. G. Toelle, D. Reeve, and others. 2015. Prevalence of airflow obstruction and reduced forced vital capacity in an Aboriginal Australian population: The cross-sectional BOLD study. *Respirology*. 2015 Jul;20(5):766-74.

Davies, H. R., L. Richeldi, and E. H. Walters. 2003. Immunomodulatory agents for idiopathic pulmonary fibrosis. *Cochrane Database of Systematic Reviews* 3: CD003134.

Devakumar, D., J. Stocks, J. G. Ayres, J. Kirkby, S. K. Yadav, and others. 2015. Effects of antenatal multiple micronutrient supplementation on lung function in mid-childhood: follow-up of a double-blind randomised controlled trial in Nepal. *Eur Respir J*. 45 (6): 1566-75.

Dockery, D. W., F. E. Speizer, B. G. Ferris, J. H. Ware, T. A. Louis, and A. Spiro. 1988. Cumulative and Reversible Effects of Lifetime smoking on Simple Tests of Lung Function in Adults. *Amer Rev Respir Dis*. 137: 286-92.

Durham, S. R., S. M. Walker, E. M. Varga, M. R. Jacobson, F. O'Brien, and others. 1999. Long-term clinical efficacy of grass-pollen immunotherapy. *New England Journal of Medicine* 341: 468-75.

Eaton, T., J. E. Garrett, P. Young, W. Fergusson, J. Kolbe, and others. 2002. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. *Eur Respir J*. 20 (2): 306-12.

Ehrlich, R. I., N. White, R. Norman, R. Laubscher, K. Steyn, and others. 2004. Predictors of chronic bronchitis in South African adults. *Int J Tuberc Lung Dis* 8 (3): 369-76.

English, R. G., M. O. Bachmann, E. D. Bateman, M. Zwarenstein, L. R. Fairall, and others. 2006. Diagnostic accuracy of an integrated respiratory guideline in identifying patients with respiratory symptoms requiring screening for pulmonary tuberculosis: a cross-sectional study. *BMC Pulmonary Medicine* 6:22.

English, R. G., E.D. Bateman, M. F. Zwarenstein, L. R. Fairall, A. Bheekie, and others. 2008. Development of a South African integrated syndromic respiratory disease guideline for primary care. *Prim Care Respir J* 17:156-63.

Erhola, M., R. Mäkinen, K. Koskela, V. Bergman, T. Klaukka, and others. 2003. The Asthma Programme of Finland: an evaluation survey in primary health care. *Int J Tuberc Lung Dis*. 7 (6): 592–98.

Evans, D. J., A. Bara, and M. Greenstone. 2007. Prolonged antibiotics for purulent bronchiectasis in children and adults. *Cochrane Database of Systematic Reviews* 2. [Q: Complete]

- Fairall, L. R., M. O. Bachmann, C. Lombard, V. Timmerman, K. Uebel, M. Zwarenstein, and others. 2012. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. *The Lancet* 380 (9845): 889-98.
- Fairall, L. R., M. O. Bachmann, G. M. Louwagie, C. van Vuuren, P. Chikobvu, D. Steyn, and others. 2008. Effectiveness of antiretroviral treatment in the South African public-sector programme: cohort study. *Arch Intern Med* 168 (1): 86-93.
- Fairall, L. R., M. O. Bachmann, M. Zwarenstein, E. D. Bateman, L. W. Niessen, and others. 2010. Cost-effectiveness of educational outreach to primary care nurses to increase tuberculosis case detection and improve respiratory care: economic evaluation alongside a randomised trial. *Trop Med Int Health* 15 (3): 277-86.
- Fairall, L. R., M. Zwarenstein, E. D. Bateman, M. Bachmann, C. Lombard, and others. 2005. Effect of educational outreach to nurses on tuberculosis case detection and primary care of respiratory illness: pragmatic cluster randomised controlled trial. *BMJ* 331 (7519): 750-54.
- Ferreira, A., C. Garvey, G. L. Connors, L. Hilling, J. Rigler, and others. 2009. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. *Chest* 135 (2): 442-47.
- Fletcher, C. M., R. Peto, C. Tinker, and F. E. Speizer. 1976. *The Natural History of Chronic Bronchitis and Emphysema: An 8 year Study of Working Men in London*. Oxford: Oxford University Press.
- Fried, L. P., R. A. Kronmal, A. B. Newman, D. E. Bild, M. B. Mittelmark, and others. 1998. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. *Journal of the American Medical Association* 279 (8): 585-92.
- Fuertes E, Bracher J, Flexeder C, Markevych I, Klümper C, Hoffmann B, Krämer U, von Berg A, Bauer CP, Koletzko S, Berdel D, Heinrich J, Schulz H. Long-term air pollution exposure and lung function in 15 year-old adolescents living in an urban and rural area in Germany: The GINIplus and LISAplus cohorts. *Int J Hyg Environ Health*. 2015;218(7):656-65.
- Georgeu, D. CC, Lewin S, L. R. Fairall, M. O. Bachmann, K. Uebel, and others. 2012. Implementing nurse-initiated and managed antiretroviral treatment (NIMART) in South Africa: qualitative process evaluation of the STRETCH trial. *Implement Sci* 7: 66.
- Gershon, A. S., G. C. Mcreedy, J. Guan, J. C. Victor, R. Goldstein, and T. To. 2015. Quantifying comorbidity in individuals with COPD: a population study. *Eur Respir J*. 45 (1): 51-59.
- Gibson, P. G., V. M. McDonald, and G. B. Marks. 2010. Asthma in older adults. *The Lancet* 376 (9743): 803-13.
- GINA (Global Initiative for Asthma). 2014. Global strategy for asthma management and prevention (revised 2014)[24/08/2014]. <http://www.ginasthma.com>.
- Glazer, C. S. 2015. Chronic hypersensitivity pneumonitis: important considerations in the work-up of this fibrotic lung disease. *Curr Opin Pulm Med*. 21 (2): 171-77.
- Global Initiative for Chronic Obstructive Lung Disease. 2014. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. [Q: Complete] <http://www.goldcopd.com/>.



Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Medical Communications Resources, Inc; 2014 [October 13, 2014]. 94].

[Ahttp://www.goldcopd.org/uploads/users/files/GOLD\\_Report\\_2014\\_Jun11.pdf](http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdf).

Graham ID, Logan J, Harrison MB, Straus SE, Tetroe J, et al. 2006. Lost in knowledge translation: time for a map? . *J Contin Educ Health Prof* 26: 13-24.

Güell, R., P. Casan, J. Belda, M. Sangenis, F. Morante, and others. 2000. Long-term effects of outpatient rehabilitation of COPD: A randomized trial. *Chest* 117: 976-83.

Haahtela, T., T. Klaukka, K. Koskela, M. Erhola, L. A. Laitinen, and the Working Group of the Asthma Programme in Finland. 2001. Asthma programme in Finland: a community problem needs community solutions. *Thorax* 56: 806-14.

Haahtela, T., L. E. Tuomisto, A. Pietinalho, T. Klaukka, M. Erhola, and others. 2006. A 10 year asthma programme in Finland: major change for the better. *Thorax* 61: 663-70.

Hamzaoui, A., and S. Ottmani. 2012. Practical approach to lung health: lung health for everyone? *Eur Respir Rev* 21: 186–95.

Han, M. K., D. S. Bach, P. G. Hagan, E. Yow, K. R. Flaherty, and others. 2013. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. *Chest* 143 (6): 1699-708.

Hankinson, J. L., J. R. Odencrantz, and F. B. Fedan. 1999. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 159 (1): 179-87.

Hansell A, Ghosh RE, Blangiardo M, Perkins C, Vienneau D, Goffe K, Briggs D, Gulliver J. Historic air pollution exposure and long-term mortality risks in England and Wales: prospective longitudinal cohort study. *Thorax* 2016;71:330–338.)

Hart, A., K. Sugumar, S. J. Milan, S. J. Fowler, and I. Crossingham. 2014. Inhaled hyperosmolar agents for bronchiectasis. *Cochrane Database of Systematic Reviews* 5.

Hill, A. T., M. Pasteur, C. Cornford, S. Welham, and D. Bilton. 2011. Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. *Prim Care Respir J* 20 (2): 135-40.

Holland, W. W., and D. D. Reid. 1965. The urban factor in chronic bronchitis. *The Lancet* 40: 445-48.

Hooper R, Calvert J, Thompson RL, Deetlefs ME, Burney, P. Urban/rural differences in diet and atopy in South Africa. *Allergy* 2008; 63: 425–431

Hooper, R., and P. Burney. 2013. Cross-sectional relation of ethnicity to ventilatory function in a West London population. *Int J Tuberc Resp Dis.* 17 (3): 400-05.

Hooper, R., P. Burney, W. Vollmer, M. McBurnie, T. Gislason, and others. 2012. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. *Eur Respir J.* 39 (6): 1343-53.

Hutchinson, J. P., T. M. McKeever, A. W. Fogarty, V. Navaratnam, and R. B. Hubbard. 2014. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. *Ann Am Thorac Soc*. 11: 1176-85.

Hwang, Y. I., J. H. Kim, C. Y. Lee, S. Park, Y. B. Park, and others. 2014. The association between airflow obstruction and radiologic change by tuberculosis. *J Thorac Dis* 6 (5): 471-76.

Iepsen, U. W., K. J. Jørgensen, T. Ringbæk, H. Hansen, C. Skrubbeltrang, and P. Lange. 2015. A combination of resistance and endurance training increases leg muscle strength in COPD: An evidence-based recommendation based on systematic review with meta-analyses. *Chron Respir Dis* 2015 May;12(2):132-45.

Jaakkola, M. S., P. Ernst, J. J. K. Jaakkola, L. W. N'Gan'ga, and M. Becklake. 1991. Effect of cigarette smoking on evolution of ventilatory lung function in young adults: an eight year longitudinal study. *Thorax* 46: 907-13.

Jiang, C., H. Huang, Liu J, Wang Y, Lu Z, Xu Z. 2012. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. *PLoS One* 7(10): e47024.

Jindal SK, Agarwal R. 2012. Long-term oxygen therapy. *Expert Rev Respir Med*. 6 (6): 639-49.

Jindal, S. K., A. N. Aggarwal, K. Chaudhry, S. K. Chhabra, G. A. D'Souza, and others. 2006. A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. *Indian J Chest Dis & Allied Sci*. 48 (1): 23-29.

Jithoo, A., P. L. Enright, P. Burney, A. S. Buist, E. D. Bateman, and others. 2013. Case-finding options for COPD: results from the Burden of Obstructive Lung Disease Study. *Eur Respir J* 41 (3): 548-55.

Kannel, W. B., E. A. Lew, H. B. Hubert, and W. P. Castelli. 1980. The value of measuring vital capacity for prognostic purposes. *Trans Assoc Life Insur Med Dir Am* 64: 66-83.

Karner, C., J. Chong, and P. Poole. 2013. Tiotropium versus placebo for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 6. [Q: Complete]

Kauffmann, F., D. Brille, and J. Lellouch. 1975. The Prognostic Value of Chronic Cough, Sputum and Spirometry Assessed by 10-Year Mortality Among 1487 Working Men. *Bulletin de Physiopathologie Respiratoire* (Nancy) 11: 45-64.

Kauppi, P., M. Linna, J. Martikainen, M. J. Mäkelä, and T. Haahtela. 2013. Follow-up of the Finnish Asthma Programme 2000–2010: reduction of hospital burden needs risk group rethinking. *Thorax* 68 (3): 292-93.

Keeley, D. J., and S. Gallivan S. 1991. Comparison of the prevalence of reversible airways obstruction in rural and urban Zimbabwean children. *Thorax* 46 (8): 549-53.

Kew, K. M., C. Mavergames, and A. E. J. Walters. 2013. Long-acting beta-2-agonists for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* (10). [Q: Complete]

Khanna, D., X. Yan, D. P. Tashkin, D. E. Furst, R. Elashoff, and others. 2007. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. *Arthritis and Rheumatism* 56 (5): 1676-84.

Kulkarni, N., N. Pierse, L. Rushton, and J. Grigg. 2006. Carbon in airway macrophages and lung function in children. *New England Journal of Medicine* 355 (1): 21-30.

Lacasse, Y., R. A. Goldstein, T. Lasserson, and S. Martin. 2006. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 4. [Q: Complete]

Lai, C. K. W., R. Beasley, J. Crane, S. Foliaki, J. Shah, and others. 2009. Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax* 64 (6): 476-83.

Lam, H. K.-B., C. Q. Jiang, R. E. Jordan, M. R. Miller, W. S. Zhang, and others. 2010. Prior TB, Smoking, and Airflow Obstruction: A Cross-Sectional Analysis of the Guangzhou Biobank Cohort Study. *Chest* 137 (3): 593-600.

Lange, P., J. Nyboe, M. Appleyard, G. Jensen, and P. Schnohr. 1990. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. *Thorax* 45: 579-85.

Larkin, E. K., Y.-T. Gao, T. Gebretsadik, T. J. Hartman, P. Wu, and others. 2015. New risk factors for adult-onset incident asthma: a nested case-control study of host antioxidant defence. *American J Respir Crit Care Medicine* 191: 45-53.

Lawlor, D. A., S. Ebrahim, and S. G. Davey. 2005. Association of birth weight with adult lung function: findings from the British Women's Heart and Health Study and a meta-analysis. *Thorax* 60 (10): 851-58.

Lee, A. L., A. Burge, and A. E. Holland. 2013. Airway clearance techniques for bronchiectasis *Cochrane Database of Systematic Reviews* 5. [Q: Complete]

Lee PN and Fry JS. Systematic review of the evidence relating FEV1 decline to giving up smoking. *BMC Medicine* 2010, 8:84

[Loth DW](#), [Soler Artigas M](#), [Gharib SA](#), [Wain LV](#), [Franceschini N](#), et al. [Q: 5 names needed]. 2014. Genome-wide association analysis identifies six new loci associated with forced vital capacity. *Nat Genet* 46 (7): 669-77.

Lozano, R., M. Naghavi, K. Foreman, S. Lim, K. Shibuya, and others 2013. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic. *The Lancet* 380 (9859): 2095-128.

Lundy Braun, L., M. Wolfgang, and K. Dickersin. 2013. Defining race/ethnicity and explaining difference in research studies on lung function. *Eur Respir J.* 41: 1362-70.

Martinez, F. D., A. L. Wright, L. M. Taussig, C. J. Holberg, M. Halonen, and others. 1995. Asthma and Wheezing in the First Six Years of Life. *New England Journal of Medicine* 332 (3): 133-38.

- Masoli, M., D. Fabian, S. Holt, and R. Beasley. 2004. The global burden of asthma: executive summary of the GINA Dissemination Committee report. *Allergy* 59 (5): 469.
- Medical Research Council Working Party. 1981. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. *The Lancet* 1: 681-86.
- Mendoza, L., P. Horta, J. Espinoza, M. Aguilera, N. Balmaceda, and others. 2015. Pedometers to enhance physical activity in COPD: a randomised controlled trial. *Eur Respir J.* 45: 347–54.
- Menezes, A. M. B., P. C. Hallal, R. Perez-Padilla, J. R. B. Jardim, A. Muiño, and others. 2007. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. *Eur Respir J* 30 (6): 1180-85.
- Menezes, A. M., F. C. Wehrmeister, F. P. Hartwig, R. Perez-Padilla, D. P. Gigante, and others. African ancestry, lung function and the effect of genetics. *Eur Respir J.* 2015 Jun;45(6):1582-9
- Miller, M. R., J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, and others. 2005. Standardisation of spirometry. *Eur Respir J* 26 (2): 153-61.
- Moffatt, M., I. Gut, F. Demenais, D. Strachan, E. Bouzigon, and others. 2010. A large-scale, consortium-based genomewide association study of asthma. *New England Journal of Medicine* 363 (13): 1211.
- National Asthma Education and Prevention Program. 2007. *Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma*. Bethesda, Maryland: National Institutes of Health, National Heart, Lung, and Blood Institute.
- Noble, P. W., C. Albera, W. Z. Bradford, U. Costabel, M. K. Glassberg, and others. Kardatz. 2011. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *The Lancet* 377 (9779): 1760-69.
- Nurmatov, U., G. Devereux, and A. Sheikh. 2011. Nutrients and foods for the primary prevention of asthma and allergy: Systematic review and meta-analysis. *J Allergy Clin Immunol* 127 (3): 724-33.
- Obaseki, D., J. Potts, G. Joos, J. Baelum, T. Haahtela, and others. 2014. The relation of airway obstruction to asthma, chronic rhinosinusitis and age: results from a population survey of adults. *Allergy* 69 (9): 1205-14.
- Office of Population. 1986. Great Britain. Office of Population C, Surveys. Occupational Mortality: The Registrar General's Decennial Supplement for Great Britain, 1979-80, 1982-83, Great Britain. Office of Population Censuses and Surveys. London: H.M. Stationery Office.
- Okubadejo, A., E. Paul, P. Jones, and J. Wedzicha. 1996. Does long-term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia? *Eur Resp J.* 9: 2335-39.
- Ottmani SE; Scherpbier R; Pio A; Chaulet P; Khaled NA. 2005. *Practical Approach to Lung Health (PAL): A Primary Health Care Strategy for Integrated Management of Respiratory Conditions in People of Five Years of Age and Over*. Geneva: WHO. Contract No.: WHO/HTM/TB/2005.351, WHO/NMH/CHP/CPM/CRA/05.3.

- Pan, L., M. Wang, X. Xie, C. Du, and Y. Guo. 2014. Effects of anabolic steroids on chronic obstructive pulmonary disease: a meta-analysis of randomised controlled trials. *PLoS One* 10 (9): e84855.
- Pedone, C., S. Scarlata, D. Chiurco, M. E. Conte, F. Forastiere, and R. Antonelli-Incalzi. 2012. Association of reduced total lung capacity with mortality and use of health services. *Chest* 141 (4): 1025-30.
- Perzanowski, M. S., P. Ngari, T. A. E. Platts-Mills, J. Odhiambo, M. D. Chapman, and others. 2002. Atopy, asthma, and antibodies to *Ascaris* among rural and urban children in Kenya. *Journal of Pediatrics* 140 (5): 582-88.
- Peto, R., F. E. Speizer, A. L. Cochrane, F. Moore, C. M. Fletcher, and others. 1983. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. *American Review of Respiratory Disease* 128 (3): 491-500.
- Phui, N. C., N. C. Tan, and T. K. Lim. 2008. Impact of the Singapore National Asthma Program (SNAP) on Preventor-Reliever Prescription Ratio in Polyclinics. *Ann Acad Med Singapore* 37: 114-17.
- Pietinalho, A., V. L. Kinnula, A. R. A. Sovijärvi, S. Vilkin, O. Säynäjäkangas, and others. 2007. Chronic bronchitis and chronic obstructive pulmonary disease. The Finnish Action Programme, interim report. *Respir Med*. 101 (7): 1419.
- Poole, P., E. E. Chacko, R. Wood-Baker, and C. J. Cates. 2006. Influenza vaccine for patients with chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 1. [Q: Complete]
- Powell, H., V. E. Murphy, D. R. Taylor, M. J. Hensley, K. McCaffery, and others. 2011. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. *The Lancet* 378 (9795): 983-90.
- Poyser MA, Nelson H, Ehrlich RI, Bateman ED, Parnell S, Puterman A, Weinberg E. Socioeconomic deprivation and asthma prevalence and severity in young adolescents. *Eur Respir J* 2002; 19: 892-898.
- Price, D., M. Fletcher, and T. van der Molen. 2014. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. *NPJ Primary Care Respiratory Medicine* 24: 1 4009.
- Raghu, G. 2013. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. *The Lancet Respir Med* 1 (5): 369-76.
- Ram, S. F. F., J. Picot, J. Lightowler, and J. A. Widzicha. 2009. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 4. [Q: Complete]
- Richeldi, L. 2012. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. *Eur Respir Rev*. 21 (124): 147-51.
- Richeldi, L., U. Costabel, M. Selman, D. S. Kim, D. M. Hansell, and others. 2011. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *New England Journal of Medicine* 365 (12): 1079-87.

- Root MM, Houser SM, Anderson JJ, Dawson HR. 2014. Healthy Eating Index 2005 and selected macronutrients are correlated with improved lung function in humans. *Nutr Res.* 34: 77-84.
- Salomon, J., H. Wang, M. Freeman, T. Vos, A. Flaxman, and others 2012. Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. *The Lancet* (North American ed). 380 (9859): 2144-62.
- Schikowski, T., M. Adam, A. Marcon, Y. Cai, A. Vierkötter, and others. 2014. Association of ambient air pollution with the prevalence and incidence of COPD. *Eur Respir J.* 44 (3): 614-26.
- Schull, M. J., R. Cornick, S. Thompson, G. Faris, L. Fairall, and others. 2011. From PALS PLUS to PALM PLUS: adapting and developing a South African guideline and training intervention to better integrate HIV/AIDS care with primary care in rural health centers in Malawi. *Implement Sci* 6: 82.
- Schultz E, Hallberg J, Bellander T, Bergström A, Bottai M, Chiesa F, Gustafsson PM, Gruzieva O, Thunqvist P, Pershagen G, Melén E. Early-Life Exposure to Traffic-related Air Pollution and Lung Function in Adolescence. *Am J Respir Crit Care Med.* 2016;193(2):171-7.
- Sembajwe, G., M. Cifuentes, S. W. Tak, D. Kriebel, R. Gore, and L. Punnett. 2010. National income, self-reported wheezing and asthma diagnosis from the World Health Survey. *Eur Respir J.* 35 (2): 279-86.
- Shaheen, S. O., J. A. C. Sterne, R. L. Thompson, C. E. Songhurst, B. M. Margetts, and others. 2001. Dietary antioxidants and asthma in adults: population based case-control study. *Amer J Respir Crit Care Med.* 164: 1823-28.
- Shulgina, L., A. P. Cahn, E. R. Chilvers, H. Parfrey, A. B. Clark, and others. 2013. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. *Thorax* 68 (2): 155-62.
- Siva, R., R. H. Green, C. E. Brightling, M. Shelley, B. Hargadon, and others. 2007. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. *European Respiratory Journal* 29 (5): 906.
- Smith, M., L. Li, M. Augustyn, O. Kurmi, J. Chen, and others. 2014. Prevalence and correlates of airflow obstruction in 317,000 never-smokers in China. *Eur Respir J* 44 (1): 66-77.
- Sodhi, S., H. Banda, D. Kathyola, M. Joshua, F. Richardson, E. Mah, and others. 2014. Supporting Middle-Cadre Health Care Workers in Malawi: Lessons Learned During Implementation of the PALM PLUS Package. *BMC Health Serv Res* 14 (S1): S8.
- Sonnappa, S., S. Lum, J. Kirkby, R. Bonner, A. M. Wade, V. Subramanya, and others. 2015. Disparities in Pulmonary Function in Healthy Children across the Indian Urban–Rural Continuum. *Am J Respir Crit Care Med* 191 (1): 79–86.
- Spagnolo, P., C. Del Giovane, F. Luppi, S. Cerri, S. Balduzzi, and others. 2010. Non-steroid agents for idiopathic pulmonary fibrosis. *Cochrane Database of Systematic Reviews* (9): CD003134.
- Speight, A. N., D. A. Lee, and E. N. Hey. 1983. Underdiagnosis and undertreatment of asthma in childhood. *Br Med J.* 286: 1253-56.

- Stein, J., S. Lewin, L. R. Fairall, P. Mayers, R. English, A. Bheekie, and others. 2008. Building capacity for antiretroviral delivery in South Africa: A qualitative evaluation of the PALS PLUS nurse training programme. *BMC Health Serv Res.* 8: 240.
- Suissa, S., P. Ernst, S. Benayoun, M. Baltzan, and B. Cai. 2000. Low-dose inhaled corticosteroids and the prevention of death from asthma. *New England Journal of Medicine* 343 (5): 332-36.
- Suissa, S., V. Patenaude, F. Lapi, and P. Ernst. 2013. Inhaled corticosteroids in COPD and the risk of serious pneumonia. *Thorax* 68 (11): 1029-36.
- Swanney, M. P., G. Ruppel, P. L. Enright, O. F. Pedersen, R. O. Crapo, and others. 2008. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. *Thorax* 63 (12): 1046-51.
- Tan, W., W. Vollmer, B. Lamprecht, D. Mannino, A. Jithoo, and others. 2012. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. *Thorax* 67: 718-26.
- Taniguchi, H., M. Ebina, Y. Kondoh, T. Ogura, A. Azuma, and others. 2015. Pirfenidone in idiopathic pulmonary fibrosis. *European Respiratory Journal* 35 (4): 821-29.
- Tashkin, D. P., R. Elashoff, P. J. Clements, J. Goldin, M. D. Roth, and others. 2006. Cyclophosphamide versus placebo in scleroderma lung disease. *New England Journal of Medicine* 354 (25): 2655-66.
- Travis, W. D., U. Costabel, D. M. Hansell, T. E. King, D. A. Lynch, and others. 2013. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 188 (6): 733-48.
- USFAD (United States Food and Drug Administration). 2010. Questions and Answers: New Safety Requirements for Long-Acting Asthma Medications called Long-Acting Beta Agonists (LABAs) Rockville, Maryland [updated 02/25/2010]. [http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm200719.htm#\\_Ref252367488](http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm200719.htm#_Ref252367488).
- Varraso, R., R. Jiang, R. G. Barr, W. Willett, C. A. Camargo, Jr. 2007. Prospective Study of Cured Meats Consumption and Risk of Chronic Obstructive Pulmonary Disease in Men. *Amer J Epidemiol* 166 (12): 1438-45.
- Vestbo, J., and J. Hogg. 2006. Convergence of the epidemiology and pathology of COPD. *Thorax* 61 (1): 86-88.
- Vietri, J., K. Burslem, and J. Su. 2014. Poor Asthma control among US workers: health-related quality of life, work impairment, and health care use. *Journal of Occupational & Environmental Medicine* 56 (4): 425-30.
- Vos, T., A. D. Flaxman, M. Naghavi, R. Lozano, C. Michaud, and others. 2012. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 380: 2163–96.



Vollenweider, D. J., H. Jarrett, C. A. Steurer-Stey, J. Garcia-Aymerich, and M. A. Puhan. 2012. Antibiotics for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 12: CD010257.

Walters, J. A. E., S. Smith, P. Poole, R. H. Granger, and R. Wood-Baker. 2010. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 11. [Q: Complete]

Walters, J. A., D. J. Tan, C. J. White, P. G. Gibson, R. Wood-Baker, and E. H. Walters. 2014. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Systematic Reviews* 9: CD001288.

Weinmayr G, Genuneit J, Nagel G, Bjorksten B, van Hage M, and others. 2010. International variations in associations of allergic markers and diseases in children: ISAAC Phase Two. *Allergy* 65 (6): 766.

WHO (World Health Organization). 2008. *Practical Approach to Lung Health: Manual on Initiating PAL Implementation*. Geneva: WHO. Contract No.: WHO/HTM/TB/2008.410, WHO/NMH/CHP/CPM//08.02. .

WHO. 2013a. *Integrated Management of Adolescent and Adult Illness (IMAI) Modules*. Geneva: WHO. <http://www.who.int/hiv/pub/imai/en/index.html>.

WHO. 2013b. Implementation tools Package of Essential Non-communicable (PEN) disease interventions for primary health care in low resource settings. Geneva: WHO.

Wilkinson, M., K. Sugumar, S. J. Milan, A. Hart, A. Crockett, and I. Crossingham. 2014. Mucolytics for bronchiectasis. *Cochrane Database of Systematic Reviews* 5. [Q: Complete]

Yang, I. A., M. S. Clarke, E. H. Sim, and K. M. Fong. 2012. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane Database Systematic Reviews* 7: CD002991.

Zemedkun, K., K. Woldemichael, and G. Tefera. 2014. Assessing control of asthma in Jush, Jimma, South West Ethiopia. *Ethiopian Journal of Health Sciences* 24 (1): 49-58.

Zwarenstein, M., L. R. Fairall, C. Lombard, P. Mayers, A. Bheekie, and others. 2011. Outreach education for integration of HIV/AIDS care, antiretroviral treatment, and tuberculosis care in primary care clinics in South Africa: PALSA PLUS pragmatic cluster randomised trial. *BMJ* 342: d2022.





## Online Box \_\_.1 Principles of Care

- **Efficacy:** Efficacy is the ability of the treatment to achieve an objective under experimental conditions. Efficacy is best tested in randomized controlled trials (RCTs); the findings may be combined in systematic reviews to arrive at more reliable assessments from which recommendations may be made.

[<http://www.cochranelibrary.com/app/content/browse/page/?context=topic/Lungs%20%26%20airways>]

Even this evidence, however, is limited by several factors: the context in which the trials have been conducted; the selection of patients, which is generally more restricted than the use of the treatment in practice; the heterogeneity of patients, who may not all have the same response to treatment; and the selection of the medication with which the medication being studied has been compared. These limitations are particularly relevant to lung diseases in low- and middle-income countries, where few RCTs have been performed and results do not necessarily apply.

- **Effectiveness of the impact of the intervention on a population.** Efficacious remedies may not be used because they are unavailable, unaffordable, or unacceptable to the patients, or they may be prescribed or used inappropriately. Inhaled drugs have a very good ratio of efficacy to side effects. However, acceptability of the inhalation route for treatment delivery is a barrier in some countries; adherence is poor unless there is a concerted effort to promote this form of treatment. Other barriers to use include high costs relative to other treatments, fear of taking corticosteroids, diverse cultural views about treatment or disease, and poor inhaler technique, particularly with pressurized metered dose inhalers (pMDIs), which require coordination of actuation with inhalation (GINA 2014; Masoli and others 2004).
- **Value for money:** Value for money is a comparative judgement generally made by the party paying for the treatment—patients, health authorities, or third-party payers. It involves comparing the relative benefit from the treatment to the benefit that could be derived from all other uses of the available resources. These judgements are not easily transferred from one person or one country to another, and relative costs and available resources may vary markedly.
- **Scalability:** Scalability is the ability to provide a good service to the whole population. Scalability requires simple algorithms (care pathways) to guide the assessment and treatment of patients (Graham and others 2006); access to quality-assured and affordable essential medicines; and inclusion of algorithms in guidelines customized both for the end users (primary care physicians and/or nurses) and for practice settings (country, facility, human and health resources and prevalent diseases and health needs) (Ottmani and others 2005).

Source: authors

References



## Box \_\_. 2: Case Study

A further example of integrated care is the PALS/PC101/PAK program. This program, developed in South Africa, began with a local version of PAL (English and others 2006; English and others 2008). After development and testing, the first version of the guideline and training program, called the Practical Approach to Lung Health in South Africa (PALS), was revised and expanded. The first revision included the chronic care of patients infected with the human immunodeficiency virus (HIV/AIDS)(PALS PLUS) (Barton and others 2013; Stein and others 2008).

The second revision included the management of approximately 80 percent of the conditions for which adult patients attend primary care clinics, including asthma, COPD, pneumonia, tuberculosis, hypertension, diabetes and several other common diseases). This program has been developed for international use as the Practical Approach to Care Kit (PAK); it has been introduced in South Africa and is being piloted in Brazil. Versions of PALS/PAK have been piloted or implemented in Malawi, Botswana, Brazil and Mexico (Schull and others 2011; Sodhi and others 2014).

This program is based on the following principles:

1. **Integration:** Silo management results in prioritization of some diseases; integration ensures their inclusion, which is particularly important for respiratory diseases that have had a low priority with little provision of resources. Integration ensures that clinicians are led through processes that consider all relevant contributing or comorbid diseases.
2. **Localization:** Integrated guidelines are context-specific, designed around locally available resources—personnel, facilities, equipment, and medications, and local or national health guidelines and prescribing provisions. In many instances, integrated guidelines help to guide policy based on review of the evidence and best-buy principles in each country. Annual updates are essential, especially for disease areas where there treatment policies change frequently.
3. **Clarity:** Integration seeks to strengthen health services by removing inconsistencies in different guidelines and providing clear recommendations for the levels and tasks of health workers. Clarity optimizes workflows, especially in resource-poor settings with heavy workloads, and facilitates task sharing (Fairall and others 2012; Georgeu and others 2012).
4. **Effective training:** Training employs modern adult learning techniques. The guideline serves as the curriculum for case-based, onsite continuing education for nurses and physicians. This training has been introduced in nursing colleges and medical schools, replacing the didactic, lecture-based, offsite training that has a poor record for changing the behavior of clinicians (Stein and others 2008; Zwarenstein and others 2011). The results of these programs have been reported in several papers, including four pragmatic cluster randomized controlled trials. These studies have confirmed consistent improvements in clinician behavior and outcomes including screening, prescribing, and referral. They have further demonstrated that the approach is highly acceptable to all categories of health teams and that users find it empowering and effective. It has resulted in concurrent improvements in the care of patients with communicable and noncommunicable diseases (Fairall and others 2005), as well as in improvements in some health outcomes (Fairall and others 2008); Fairall and others 2010) and more appropriate referrals and reductions in the length and duration of hospital admissions. Reports indicate a dose-response effect of the clinical training, confirming the effectiveness of continuing onsite education.